Metabolic imaging allows early prediction of response to vandetanib

Journal of Nuclear Medicine

Volumn 52, Issue 2, 2011, Pages 231-240

  Walter, Martin A ^a,b   Benz, Matthias R ^b   Hildebrandt, Isabel J ^b   Laing, Rachel E ^b   Hartung, Verena ^c   Damoiseaux, Robert D ^d   Bockisch, Andreas ^c   Phelps, Michael E ^b   Czernin, Johannes ^b   Weber, Wolfgang A ^b,e  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Animal imaging; Early treatment monitoring; Endocrinology; Medullary thyroid cancer; Oncology; Positron emission tomography; Tyrosine kinase inhibitor; Vandetanib

Indexed keywords

CYCLINE; DOPA; FLUORODEOXYGLUCOSE F 18; GLUCOSE; ONCOPROTEIN; REARRANGED DURING TRANSFECTION PROTEIN; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG; VANDETANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL METABOLISM; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGING; IN VIVO CULTURE; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; THYROID MEDULLARY CARCINOMA; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLINS; DIHYDROXYPHENYLALANINE; DOWN-REGULATION; FEMALE; FLUORODEOXYGLUCOSE F18; G0 PHASE; G1 PHASE; GLUCOSE; HUMANS; MALE; MICE; MICE, SCID; MICROARRAY ANALYSIS; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-RET; QUALITY CONTROL; QUINAZOLINES; RADIOPHARMACEUTICALS; RNA, NEOPLASM; SIGNAL TRANSDUCTION; THYMIDINE; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 79851504300     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.081745     Document Type: Article

References (40)

1. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006;27:535-560. (Pubitemid 44213230)
2. Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15:531-544. (Pubitemid 40993726)
3. Watanabe T, Ichihara M, Hashimoto M, et al. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am J Pathol. 2002;161:249-256. (Pubitemid 34760790)
4. Mettouchi A, Klein S, Guo W, et al. Integrin-specific activation of Rac controls progression through the G1 phase of the cell cycle. Mol Cell. 2001;8:115-127. (Pubitemid 32772910)
5. Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene. 2000;19:5419-5427. (Pubitemid 32000908)
6. Winston JT, Coats SR, Wang YZ, Pledger WJ. Regulation of the cell cycle machinery by oncogenic ras. Oncogene. 1996;12:127-134. (Pubitemid 26041248)
7. D'Amico M, Hulit J, Amanatullah DF, et al. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem. 2000;275:32649-32657.
8. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153-166.
9. Pero SC, Daly RJ, Krag DN. Grb7-based molecular therapeutics in cancer. Expert Rev Mol Med. 2003;5:1-11.
10. Patterson RL, van Rossum DB, Nikolaidis N, Gill DL, Snyder SH. Phospholipase C-gamma: diverse roles in receptor-mediated calcium signaling. Trends Biochem Sci. 2005;30:688-697. (Pubitemid 41668862)
11. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62:7284-7290. (Pubitemid 36025251)
12. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:5407-5415.
13. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am. 2008;37:511-524. (Pubitemid 351698088)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
15. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654-662. (Pubitemid 40175840)
16. Samih N, Hovsepian S, Aouani A, Lombardo D, Fayet G. Glut-1 translocation in FRTL-5 thyroid cells: role of phosphatidylinositol 3-kinase and N-glycosylation. Endocrinology. 2000;141:4146-4155.
17. Wright DC, Craig BW, Fick CA, Lim KI. The effects of phospholipase C inhibition on insulin-stimulated glucose transport in skeletal muscle. Metabolism. 2002;51:271-273. (Pubitemid 34232625)
18. Salter DW, Baldwin SA, Lienhard GE, Weber MJ. Proteins antigenically related to the human erythrocyte glucose transporter in normal and Rous sarcoma virus-transformed chicken embryo fibroblasts. Proc Natl Acad Sci USA. 1982;79:1540-1544. (Pubitemid 12074043)
19. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem. 1988;263:13655-13662.
20. Rollins BJ, Morrison ED, Usher P, Flier JS. Platelet-derived growth factor regulates glucose transporter expression. J Biol Chem. 1988;263:16523-16526. (Pubitemid 18268827)
21. Guillet-Deniau I, Pichard AL, Kone A, et al. Glucose induces de novo lipogenesis in rat muscle satellite cells through a sterol-regulatory-element- binding-protein-1c-dependent pathway. J Cell Sci. 2004;117:1937-1944. (Pubitemid 38745127)
22. Suh HN, Lee YJ, Han HJ. Interleukin-6 promotes 2-deoxyglucose uptake through p44/42 MAPKs activation via Ca2+/PKC and EGF receptor in primary cultured chicken hepatocytes. J Cell Physiol. 2009;218:643-652.
23. Hennige AM, Lammers R, Hoppner W, et al. Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology. 2001;142:4441-4447. (Pubitemid 32907074)
24. Walter MA, Seboek D, Demougin P, et al. Extraction of high-integrity RNA suitable for microarray gene expression analysis from long-term stored human thyroid tissues. Pathology. 2006;38:249-253. (Pubitemid 43879722)
25. Joost HG, Bell GI, Best JD, et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol. 2002;282:E974-E976. (Pubitemid 34654762)
26. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 2004; 447:532-542. (Pubitemid 38258215)
27. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 2004;447:735-743.
28. Kovacs MJ, Reece DE, Marcellus D, et al. A phase II study of ZD6474 (Zactima), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma: NCIC CTG IND.145. Invest New Drugs. 2006;24:529-535. (Pubitemid 44273029)
29. Holt LJ, Siddle K. Grb10 and Grb14: enigmatic regulators of insulin action-and more? Biochem J. 2005;388:393-406.
30. Deng Y, Bhattacharya S, Swamy OR, et al. Growth factor receptor-binding protein 10 (Grb10) as a partner of phosphatidylinositol 3-kinase in metabolic insulin action. J Biol Chem. 2003;278:39311-39322. (Pubitemid 37248486)
31. Su H, Bodenstein C, Dumont RA, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:5659-5667. (Pubitemid 44629592)
32. Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2- deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control. 2005;12:254-260. (Pubitemid 41552318)
33. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med. 2008;49:13-21.
34. Benz MR, Czernin J, Allen-Auerbach MS, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009;15:2856-2863.
35. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23:7445-7453. (Pubitemid 46291806)
36. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657. (Pubitemid 46606307)
37. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805. (Pubitemid 47308659)
38. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-2020. (Pubitemid 37297757)
39. 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27:439-445.
40. Drosten M, Putzer BM. Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol. 2006;3:564-74. (Pubitemid 44781726)